Table 2.

Baseline subject characteristics for primary analysis

Variable	Acute MI Group (N = 49)	Stable CAD Group (N = 15)	p value
Age (mean ± SD) years	58.6 ± 14.4	61.3 ± 8.9	0.49
Males (%)	65.3	53.3	0.54
Caucasian race (%)	77.6	93.3	0.09
Current smoker (%)	53.1	20.0	0.04
Currently consumes alcohol (%)	32.7	46.7	0.37
History of dyslipidemia (%)	46.9	86.7	0.01
History of diabetes mellitus (%)	10.2	40.0	0.03
History of hypertension (%)	61.2	93.3	0.06
History of atherosclerosis (%) (MI, CAD, PCI, CABG)	38.8	100.0	< 0.0001
History of congestive heart failure (%)	8.2	6.7	1.00
History of chronic renal failure (%)	8.2	0.0	0.28
History of stroke (%)	10.2	0.0	0.33
HR at time of presentation (mean ± SD)	85	66	< 0.0001
MAP at time of presentation (mean ± SD)	102.8 ± 24.7	91.4 ± 14.3	0.09
BMI at time of presentation (mean ± SD)	27.5 ± 7.24	33 ± 7.08	0.02
Time (h) elapsed presentation to angiogram (median ± IQR, range)	3.5 ± 16.0, 36	2.0 ± 1.0, 3	0.21b
Baseline troponin (mean ± SD, range) mg/dL	5.59 ± 10.83, 55.3	0.009 ± 0.003, 0.01	< 0.0001b
Peak troponin (mean ± SD, range)	33.5 ± 37.9, 150.3	0.008 ± 0.004, 0.01	< 0.0001b
Glucose at baseline (mean ± SD, range)	142.1 ± 56.5, 285	131.6 ± 30.6, 107	0.35a
Creatinine at baseline (mean ± SD, range)	1.13 ± 0.79, 4.34	0.92 ± 0.17, 0.66	0.10a
ST elevation on EKG at baseline	63.3	0.0	< 0.0001
At least one vessel with ≥50 % coronary stenosis on enrollment angiogram	73.5	40.0	0.03
Aspirin use at time of enrollment (%)	89.8	86.7	0.66
P2Y12 Inhibitors use at enrollment (%)	53.1	50.0	0.77

MI myocardial infarction, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, BMI body mass index, ACE-I angiotensin converting enzyme inhibitor

^aWelch’s t-test

^bWilcoxon rank-sum test